ClinicalTrialsFinder
CompletedPhase 2ACTRN12605000026628

Phase II study of fixed dose rate Gemcitabine-Oxaliplatin Integrated with concomitant 5FU and 3-D Conformal Radiotherapy for the treatment of localised pancreatic cancer: GOFURTGO

Sponsor

AGITG

Enrollment

45 participants

Start Date

Apr 13, 2005

Study Type

Interventional

Conditions

Locally advanced or locally recurrent inoperable pancreatic cancer not previously treated with chemotherapy or radiotherapy.

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This study tests a combination of chemotherapy drugs (gemcitabine, oxaliplatin, and 5FU) together with radiation therapy for pancreatic cancer that cannot be removed by surgery. People with confirmed adenocarcinoma of the pancreas in the head or body of the pancreas may be eligible. Participation involves receiving chemotherapy infusions and radiation treatments.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

All patients enrolled in the study will receive the same treatment consisting of all of the following: a) 1 cycle of chemotherapy: the cycle is 28 days (gemcitabine on days 1 and 15 and oxaliplatin o

All patients enrolled in the study will receive the same treatment consisting of all of the following: a) 1 cycle of chemotherapy: the cycle is 28 days (gemcitabine on days 1 and 15 and oxaliplatin on days 2 and 16, followed by: b)radiotherpay plus continuous 5FU infusion: 5FU is given continuously (7 days a week for 6 weeks), radiotherpay is given 5 days a week (Mon-Fri) for 6 weeks followed by: c) 3 cycles of chemotherapy: each cycle is 28 days (gemcitabine on days 1 and 15 and oxaliplatin on days 2 and 16

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000026628